Natiijooyinka daraasadda LUX-Sambabada 7 waxay muujinaysaa in daraasad madax-ilaa-madaxa ah oo Wajiga IIb ah la barbar dhigo afatinib iyo gefitinib ee daaweynta burooyinka leh isbeddellada EGFR Natiijooyinka waxaa lagu daabacay majaladda "Lancet Oncology".
Madaxa cilmi-baarista iyo qoraaga koowaad ee LUX-Lung 7, Keunchil Park, oo ah agaasimaha Machadka Caafimaadka Kansarka Cusub (ICMI) ee Xarunta Caafimaadka ee Samsung, waa borofisar ka tirsan Kuliyadda Caafimaadka ee Jaamacadda Sungkyunkwan ee Seoul, South Korea, "Furaha Natiijooyinka ka soo baxay daraasaddan ayaa muujinaya in Alfa Tinib iyo gefitinib ay ku kala duwan yihiin wax ku oolnimada inta u dhaxaysa dhibco badan oo dhammaadka ah iyo kooxo-hoosaadyada bukaanka ee hore loo sii qeexay. "
Natiijooyinka tijaabada bukaan-socodka ee LUX-Sambabada 7 ayaa muujinaya in afatinib ay si weyn u yareeyn karto halista kansarka sanbabada Horumarka 27% marka loo eego gefitinib. Hagaajinta badbaadada-horumar la'aanta (PFS) waxay soo ifbaxday muddo ka dib. Qiyaastii 2 sano ka dib dhammaadka daawaynta, tirada bukaannada helay afatinib weli waa nool yihiin oo cudurku ma uusan soo bixin wax ka badan laba jeer tirada bukaannada qaata gefitinib (18 bilood ka dib; 27% vs. 15% iyo 24 bilood ka dib; 18) % Vs.
Intaa waxaa dheer, muddada daawaynta ee afatinib ayaa aad uga dheerayd tan gefitinib, iyo heerka guuldarada daaweynta ayaa hoos loo dhigay 27%. Marka la barbardhigo gefitinib, bukaanada helay afatinib waxay lahaayeen ujeedo aad u sareysa buro heerka jawaabta (ORR; tusmaynta macnaha kiliinikada ee dhimista cabbirka burada) (70% vs 56%), oo leh muddada jawaabta dhexdhexaadka ah ee 10.1 Bisha vs. 8.4 bilood. Wadarta guud ee badbaadada wadajirka ah ee bar dhamaadka aasaasiga ah (OS) weli ma qaan gaarin waxaana lagu dhawaaqi doonaa mustaqbalka.
Imtixaanka bukaan-socodka ee LUX-Sambabada 7, afatinib iyo gefitinib waxay muujiyeen horumarin isku mid ah oo ku saabsan cabbirada waxtarka ee bukaan-socodka ee la soo sheegay, iyo afatinib si weyn ugama duwana tayada nolosha ee la xiriirta caafimaadka marka loo eego daaweynta gefitinib. Labada daawaynta afatinib iyo gefitinib si fiican ayaa loo dulqaatay guud ahaan, taasoo keentay in si siman loo joojiyo (6%) marka la eego joojinta ay sababtay daawaynta.
Wadarta inta jeer ee dhacdooyinka xun xun waxay ahaayeen afatinib 44.4% iyo gefitinib 37.1%. Dhacdooyinka xun xun ee ugu badan ee fasalka afatinib ≥3 waa: shuban (13%) iyo finan / finanka (9%), gefitinib: aspartate aminotransferase (AST) / alanine aminotransferase (ALT) kordhay (9%), finan / finanka (3). %) Afar xaaladood oo ah cudurka sambabada interstitial ee gefitinib ayaa la soo sheegay, midna kuma dhicin bukaannada afatinib. Si loo maareeyo dhacdooyinka taban (AEs) si wanaagsan loo maareeyo, isbeddelada qiyaasta qiyaasta afatinib ayaa suurtagal ah bukaannada qaarkood oo buuxiya shuruudo. Sababtoo ah gefitinib kaliya waxay isticmaali kartaa hal qiyaas, laguma siin karo qiyaas yar.
LUX-Sambabada 7 waa tijaabadii labaad ee madax-ilaa-madaxa ee afatinib si loo barbardhigo jiilka kowaad ee EGFR tyrosine kinase inhibitor (TKI). Tijaabadii ugu horeysay ee bukaan-socod LUX-Lung 8 marka la barbar dhigo afatinib iyo erlotinib ee daawaynta kansarka sambabada unugyada squamous.
Aad ayaan ugu faraxsanahay in majaladda "Lancet Oncology" ay daabacday natiijooyinka LUX-Sambabada 7 tijaabada caafimaadka waxaanan aaminsanahay in natiijooyinkan lagu dabaqi karo daaweynta EGFR-mutated. kansarka sanbabada ee aan yareyn. "Boehringer Ingelheim Oncology Development Clinical and Medical Guddoomiye kuxigeenka Tarek Sahmoud, MD, Doctor of Science." LUX-Lung 7 waa tijaabo caafimaad oo madax-ilaa-madax ah oo ku salaysan waayo-aragnimada bukaan-socodkeena, taasoo muujinaysa sida ay nooga go'an tahay in afatinib si fiican loo sameeyo go'aan qaadashada fahamka iyo isticmaalka."
